Siegfried Secures Antitrust Approval for Acquisition of U.S. and Australian Sites

Siegfried AG has obtained antitrust clearance for its acquisition of three drug substance sites in the U.S. and Australia. The transaction is set to close on May 1, 2026, and involves sites in Wilmington, Delaware; Athens, Georgia; and Westbury, Tasmania. These sites bring an additional 400 employees into Siegfried's network.

The acquisition aligns with Siegfried's EVOLVE+ strategy and aims to boost the company's synthesis business. This includes leveraging Wilmington's manufacturing capacity and Athens' development capabilities. This expansion is expected to contribute approximately USD 100 million in net sales for 2026, growing to USD 155 million annually.

Siegfried anticipates high-single-digit sales growth in local currencies for both its Drug Substance and Drug Products clusters. The company continues to target a core EBITDA margin above 23% and remains optimistic about sustaining profitable growth beyond market expectations.